Clinical Trials on Fallopian Tube Mucinous Adenocarcinoma

Total 994 results

Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage I Colon Cancer | Stage I Rectal Cancer
University College, London
Merck Sharp & Dohme LLC

Active, not recruiting

Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer (PROMPT)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United Kingdom
Beth Israel Deaconess Medical Center
National Cancer Institute (NCI); Massachusetts General Hospital; Dana-Farber...

Completed

Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Masonic Cancer Center, University of Minnesota

Terminated

Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
ImmunoVaccine Technologies, Inc. (IMV Inc.)

Completed

Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Canada
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8

United States
Centre Oscar Lambret
Institut National de la Santé Et de la Recherche Médicale, France

Active, not recruiting

Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer (TILsOV-1805)

Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Fallopian Tube Cancer Stage IIIC | Fallopian Tube Cancer Stage IV

France
Northwestern University

Terminated

Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Eli Lilly and Company; Genentech, Inc.; Brigham... and other collaborators

Terminated

Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Royal College of Obstetricians and Gynecologists

Completed

Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United Kingdom
Hoffmann-La Roche
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Completed

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

Korea, Republic of, United States, Italy, Belgium, Australia, France, Austria, China, Denmark, Germany, Greece, Spain, Sweden, Japan, Russian Federation, Turkey, Norway, Brazil, Czechia, Finland, Poland, Israel
Duke University
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Uterine Endometrial Cancer

United States
AstraZeneca

Completed

Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India (BRCA)

Ovarian Cancer

India
Columbia University

Terminated

A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers (HIPEC)

Fallopian Tube Cancer | Recurrent Ovarian Cancer

United States
Herbert Irving Comprehensive Cancer Center

Unknown

Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cavity Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Recurrent Ovarian Germ Cell Tumor | Undifferentiated Ovarian Carcinoma | Ovarian Serous...

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IIIA Fallopian Tube Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA Primary Peritoneal Cancer AJCC v8 | Stage IIIA1 Fallopian Tube Cancer AJCC v8 | Stage... and other conditions

United States
Daiichi Sankyo
Merck Sharp & Dohme LLC

Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Solid Cancer

Japan, China, Taiwan, Korea, Republic of
M.D. Anderson Cancer Center

Recruiting

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Ovarian Cancer | Fallopian Tube Cancer

United States
M.D. Anderson Cancer Center
AstraZeneca; Aravive Biologics Inc

Active, not recruiting

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States
John Hays
Sanofi

Unknown

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage IV Colon Cancer | Stage IV Rectal Cancer

United States
Ronald Buckanovich
Genentech, Inc.

Recruiting

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

PARP Inhibitor | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Hedgehog Inhibitor

United States
TetraLogic Pharmaceuticals

Completed

Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

Relapsed Epithelial Ovarian Cancer | Relapsed Primary Peritoneal Cancer | Relapsed Fallopian Tube Cancer

United States
Abramson Cancer Center at Penn Medicine

Active, not recruiting

Nudge to Gynecologic Oncology

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC; ImmunoVaccine Technologies, Inc. (IMV Inc.)

Active, not recruiting

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Advanced Cancer | Primary Peritoneal Carcinoma

Canada
Abramson Cancer Center of the University of Pennsylvania

Completed

Pelvic Floor Disorders in Survivors of Gynecologic Malignancies

Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Vulvar Cancer | Peritoneal Cancer | Uterine Cancer

United States
Amgen

Completed

Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer
AA Secord

Completed

PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients (MITO23)

Ovarian Neoplasms

Italy
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Andreana Holowatyj, PhD, MSCI

Recruiting

Genetics of Appendix Cancer Study (GAP)

Appendix Cancer | Appendiceal Neoplasms | Appendix Adenocarcinoma | Appendiceal Cancer | Appendiceal Adenocarcinoma | Appendix Tumor | Appendiceal Mucinous Neoplasm | Appendiceal Carcinoid Tumor | Appendiceal Neoplasm Malignant Secondary | Appendix Mucinous Neoplasm | Appendix Cancer Metastatic | Appendix NET | Low-Grade Appendix Mucinous Neoplasm and other conditions

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage III Ovarian Cancer | Stage III Fallopian Tube Cancer | Stage II Ovary Cancer | Stage II Ovarian Cancer | Stage III Ovary Cancer and other conditions

United States
Roswell Park Cancer Institute

Active, not recruiting

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Refractory Ovarian... and other conditions

United States
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute

Completed

Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Brigham and Women's Hospital

Terminated

Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Mixed Tumor, Mesodermal

United States
Sutro Biopharma, Inc.

Active, not recruiting

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Ovarian Carcinoma | Endometrioid Adenocarcinoma | Ovary Cancer | Primary Peritoneal Carcinoma

United States, Spain
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Completed

RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage IV Primary Peritoneal Cancer

United States, Canada
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Recruiting

Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients (ACAPP)

Pseudomyxoma Peritonei

Italy
Ruijin Hospital

Not yet recruiting

Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer

Fallopian Tube Cancer | Peritoneal Cancer | Primary Ovarian Cancer
British Columbia Cancer Agency
Ozmosis Research Inc.

Unknown

PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

Canada
Mayo Clinic

Not yet recruiting

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Recurrent... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Incyte Corporation

Active, not recruiting

Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Cancer | Recurrent Epithelial Ovarian Cancer | Recurrent Peritoneal Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Peritoneal Carcinoma | Stage III Fallopian Tube Cancer | Stage II Fallopian Tube Cancer | Ovarian Epithelial Cancer Stage I | Ovarian Epithelial Cancer Stage II | Ovarian Epithelial Cancer Stage III | Stage I Fallopian Tube Cancer

United States
M.D. Anderson Cancer Center

Recruiting

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Recruiting

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Ovarian Cancer Stage IV | Ovarian Cancer Stage III | Fallopian Tube Cancer Stage IV | Fallopian Tube Cancer Stage III

United States

Clinical Trials on Fallopian Tube Mucinous Adenocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations